Loading stock data…
$13.84-0.46 (-3.22%)
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.
NovoCure Limited in the Healthcare sector is trading at $13.84 with a market capitalization of $2.0B. Wall Street consensus targets $26.86 (7 analysts), implying a +94.1% move over the next 12 months. The stock is currently 35% below its 52-week high of $21.45, remaining 6.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $183.58M↑ | $174.06M↓ | $174.35M↑ | $167.20M↑ | $158.81M |
| Gross Profit | $142.48M↑ | $135.13M↑ | $132.19M↑ | $122.47M↑ | $117.33M |
| Operating Income | -$10.56M↑ | -$67.42M↓ | -$40.39M↓ | -$36.02M↑ | -$39.52M |
| Net Income | -$15.66M↑ | -$71.14M↓ | -$24.50M↑ | -$37.27M↑ | -$40.14M |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, an...